The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo-Controlled Comparison of BID versus TID Dosing
Abstract
Pregabalin is a new anxiolytic that acts as a presynaptic inhibitor of the release of excessive levels of excitatory neurotransmitters by selectively binding to the alpha2-delta subunit of voltage-gated calcium channels. The current study evaluated the anxiolytic efficacy of BID versus TID dosing of pregabalin in patients with generalized anxiety disorder. Outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition generalized anxiety disorder and having baseline Hamilton Anxiety (HAM-A) total scores > or =20 were randomized to 6 weeks of double-blind treatment with pregabalin 200 mg/d (BID; N = 78), 400 mg/d (BID; N = 89), or 450 mg/d (TID; N = 88) or placebo (N = 86). Mean improvement in HAM-A total score at last observation carried forward end point was significantly greater on pregabalin 200 (P = 0.006), 400 (P = 0.001), and 450 mg/d (P = 0.005) compared with placebo. Pairwise comparisons of BID versus TID dosing found no difference in HAM-A change score at end point. All 3 pregabalin dosage groups showed significantly greater efficacy versus placebo at end point on the HAM-A psychic and somatic anxiety factor scores. Improvement on both factors was rapid: significance versus placebo was achieved as early as the first assessment at week 1, with > or =30% reduction in HAM-A severity and equal or greater improvement for every subsequent visit in > or =38% of patients in all 3 pregabalin dosage groups (P < or = 0.001). Pregabalin was well tolerated, and despite the fixed-dose study design, discontinuations caused by adverse events ranged from 9% to 13%--comparable with that observed with placebo (8%). This study demonstrates that pregabalin is an effective treatment of generalized anxiety disorder, with BID dosing showing similar efficacy and comparable tolerability with TID dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Pregabalin [576,577,592,593,597,613] 1 Buspirone [108,561,572,589,598,618,619] 1”
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Taylor, C. P., Angelotti, T., & Fauman, E. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.09.008 · Cited by 565
Siddall, P. J., Cousins, M. J., Otte, A., Griesing, T., Chambers, R., & Murphy, T. K. (2006) · Neurology · doi:10.1212/01.wnl.0000244422.45278.ff · Cited by 398
Tassone, D. M., Boyce, E., Guyer, J., & Nuzum, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.013 · Cited by 275
Metadata
- Authors
- Pohl, R. B., Feltner, D. E., Fieve, R. R., & Pande, A. C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2005-04
- Volume
- 25
- Issue
- 2
- Pages
- 151-158
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2084250730
- Cited by
- 168
- References
- 3
- FWCI
- 24.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo-Controlled Comparison of BID versus TID Dosing. https://app.cochat.ai/papers/10.1097/01.jcp.0000155820.74832.b0
- The paper
- Pohl, R. B., Feltner, D. E., Fieve, R. R., & Pande, A. C. (2005). Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo-Controlled Comparison of BID versus TID Dosing. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000155820.74832.b0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.